Health Aspects of Cannabis

Leo E. Hollister

Veterans Administration Medical Center
and Stanford University School of Medicine,
Palo Alto, California


PHARMACOLOGICAL REVIEWS
Copyright © 1986
by The American Society for Pharmacology
and Experimental Therapeutics



V. Summary

TOC

Marijuana seems firmly established as another social drug in Western countries, regardless of its current legal status. Patterns of use vary widely. As with other social drugs, the pattern of use is critical in determining adverse effects on health. Perhaps the major area of concern about marijuana is among the very young. Using any drug on a regular basis that alters reality may be detrimental to the psychosocial maturation of young persons. Chronic use of marijuana may stunt the emotional growth of youngsters. Evidence for an amotivational syndrome is largely based on clinical reports; whether marijuana use is a cause or effect is uncertain. A marijuana psychosis, long rumored, has been difficult to prove. No one doubts that marijuana use may aggravate existing emotional disorders. Brain damage has not been proved. Physical dependence is rarely encountered in the usual patterns of social use, despite some degree of tolerance that may develop. The endocrine effects of the drug might be expected to delay puberty in prepubertal boys, but actual instances have been rare. As with any material that is smoked, chronic smoking of marijuana will produce bronchitis; emphysema or lung cancer have not yet been documented. Cardiovascular effects of the drug are harmful to those with preexisting heart disease; fortunately the number of users with such conditions is minimal. Fears that the drug might accumulate in the body to the point of toxicity have been groundless. The potential deleterious effects of marijuana use on driving ability seem to be self-evident; proof of such impairment has been more difficult. The drug is probably harmful when taken during pregnancy, but the risk is uncertain. One would be prudent to avoid marijuana during pregnancy, just as one would do with most other drugs not essential to life or well-being. No clinical consequences have been noted from the effects of the drug on immune response, chromosomes, or cell metabolites. Contamination of marijuana by spraying with defoliants has created the clearest danger to health; such attempts to control production should be abandoned.

Therapeutic uses for marijuana, THC, or cannabinoid homologs are being actively explored. Only the synthetic homolog, nabilone, has been approved for use to control nausea and vomiting associated with cancer chemotherapy. While little doubt remains that marijuana, THC, and nabilone are effective for this use, the advent of other drugs that are equally effective but with fewer adverse effects may make this use moot. Use of marijuana to reduce intraocular pressure in patients with glaucoma requires a feasible topical preparation of cannabinoids. Although some cannabinoids have analgesic activity, the abundance of new opioid analgesics with little dependence liability provides tough competition. The use of marijuana as a muscle relaxant, though promising, has not yet been adequately studied. Clinical studies to establish the efficacy of cannabidiol as an anticonvulsant or to compare it with other anticonvulsants are still to be done. Other potential therapeutic uses, such as treatment of bronchitis, asthma, insomnia, hypertension, abstinence syndromes, migraine, anorexia, and alcoholism, are most unlikely prospects.

Compared with other licit social drugs, such as alcohol, tobacco, and caffeine, marijuana does not pose greater risks. One would wonder, however, if society were given a choice based on current knowledge, whether these drugs would have been granted their present status of acceptance. Marijuana may prove to have greater therapeutic potential than these other social drugs, but many questions still need to be answered.

TOC


"ARM YOURSELF"


REFERENCES

TOC

1. Abboud, T.T., and Sanders, H.D.: Effect of oral administration of delta-9-tetrahydrocannabinol on airway mechanics in normal and asthmatic subjects. Chest 70: 480-485, 1976.

2. Abel, E.L.: The relationship between cannabis and violence: a review. Psychol. Bull 84: 193-211, 1977

3. Abel, E.L.: Prenatal exposure to cannabis. A critical review of effects on growth, development, and behavior. Behav. Neural. Biol. 29: 137-156, 1980.

4. Abel, E.L.: Marijuana and sex. A critical survey. Drug Alcohol Depend. 8: 1-22, 1981.

5. Abruzzi, W.: Drug induced psychosis. Int. J. Addict. 121: 183-193, 1977.

6. Allen, T.: Tetrahydrocannabinol and chemotherapy. N. Engl. J. Med. 294: 168, 1976.

7. Annis, H.M., and Smart, R.G.: Adverse reactions and occurrences from marijuana use. Br. J. Addict. 68: 315-319, 1973.

8. Anonymous Editorial. Cannabis and the cardiovascular system. Br. Med. J 1: 460, 1978.

9. Aronow, S., and Cassidy, J.: Effect of marijuana and placebo-marijuana on angina pectoris. N. Engl. J. Med. 291: 65-67, 1974.

10. Aronow, S., and Cassidy, J.: Effect of smoking marijuana and of a high nicotine cigarette on angina pectoris. Clin. Pharmacol. Ther. 17: 549-554, 1975.

11. Ayalon, D., and Tsafriri, A.: Suppression of the cyclic surge of luteinizing hormone secretion and of ovulation in the rat by delta-1-tetrahydrocannabinol. Nature (Lond.) 243: 470-471, 1973.

12. Bannerjee, B. N., Galbreath, C., and Sofia, R.D.: Teratologic evaluation of synthetic delta-9-tetrahydrocannabinol in rats. Teratology 11: 99-102, 1975.

13. Belleville, J.W., Gasser, J.C., and Miyake, T.: Tolerance to the respiratory effects of marijuana in man. J. Pharmacol. Exp. Ther. 197: 326-331, 1976.

14. Belleville, J.W., Swanson, G.D., Halderman, G., Aqleh, K., and Sato, T.: Respiratory effects of tetrahydrocannabinol, pentobarbital, and alcohol. Proc. West. Pharmacol. Soc. 17: 215-218, 1974.

15. Bensusan, S.D.: Marijuana withdrawal symptoms, Br. Med. J. 1: 112, 1971.

16. Binitie, A.: Psychosis following ingestion of hemp in children. Psychopharmacologia 44: 301-302, 1975.

17. Blevins, R.D., and Regan, J.D.: Delta-9-tetrahydrocannabinol effect on macromolecular synthesis in human and other mammalian cells. Arch. Toxicol. 34: 127-135, 1976.

18. Borgen, A., Davis, W.M., and Pace, H.B.,: Effects of prenatal delta-9-tetrahydrocannabinol on the development of rat offspring. Pharmacol. Biochem. Behav. 1: 203-206, 1973.

19. Bradley, S.G., Munson, A.E., Dewey, W.L., and Harris, L.S.: Enhanced susceptibility of mice to combinations of delta-9-tetrahydrocannabinol and live or killed gram negative bacteria. Infect. Immun. 17: 325-329, 1977.

20. Braunstein, G.D., Buster, J.E., Soares, J.R., and Gross, S.J.: Pregnancy hormone concentrations in marijuana users. Life Sci. 33: 195-199, 1983.

21. Burstein, S., Hunter, S.a., and Sedor, C.:Further studies in the inhibition of Leydig cell testosterone synthesis by delta-1-tetrahydrocannabinol. Biochem. Pharmacol. 29: 2152-2154, 1980.

22. Campbell, A.M.G., Evans, M., Thompson, J.L.G., and Williams, M.R.: Cerebral atrophy in young cannabis smokers. Lancet 2: 1219-1224, 1971.

23. Carlen, P.L., Wortzman, G., Holgate, R.C., Wilkerson, D.A., and Rankin, R.G.: Reversible cerebral atrophy in recently abstinent chronic alcholics measured by computed tomography scans. Science (Wash. DC) 200: 1076-1078, 1978.

24. Carlen, A.S., and Truoin, E.W.: The effect of long term chronic marijuana use on neuropsychological functioning. Int. J. Addict. 1275: 617-624, 1977.

25. Carlini, E.A., and Cunha, J.A.: Hypnotic and antiseptic effects of cannabidiol. J. Clin. Pharmacol. 21: 417S-427S, 1981

26. Carter, W.E., Doughty, P.C.: Social and cultural aspects of cannabis use in Costa Rica. Ann. NY Acad. Sci. 282: 2-16, 1976.

27. Cates, W., and Pop, J.N.: Gynecomastia and cannabis smoking- a non-association among US Army soldiers. Am J. Surg. 134: 613-615, 1977.

28. Chang, A.E., Shiling, D.J., Stillman, R.C., Goldberg, N., Seipp, C., Barofsky, I., Simon, R. and Rosenberg, S.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate; a prospective, randomized evaluation. Ann. Int. Med. 91: 819-824, 1979.

29. Chesher, G.B. and Jackson, D.M.: Anticonvulsant effects of cannabinoids in mice. Drug interactions with cannabinoids and cannabinoid intractions with phenytoin. Psychopharmacologia 37: 255-264, 1974.

30. Chopra, G.S., and Smith, J.W.: Psychotic reactions following cannabis use in East Indians. Arch. Gen. Psychiatry 30: 24-27, 1974.

31. Chronic cannabis use. NY Acad. Sci. 282: 1-430, 1976.

32. Clark, S.C., Greene, C., Karr, G.W., Maccannell, K.L., and Milstein, S.L.: Cardiovascular effects of marijuana in man. Can. J. Physiol. 52: 706-719, 1974.

33. Co, B.T., Goodwin, D.W., Gado, M., Mikhael, M., and Hill, S.Y.: Absence of cerebral atrophy in chronic cannabis users by computerized transaxial tomography. J. Am. Med. Assoc. 237: 1229-1230, 1977.

33. Co, B.T., Goodwin, D.W., Gado, M., Mikhael, M., and Hill, S.Y.: Absence of cerebral atrophy in chronic cannabis users by computerized transaxial tomography. J. Am. Med. Assoc. 237: 1229-1230, 1977.

34. Coggins, W.J.: Costa Rica cannabis project: an interim report on the medical aspects. In Pharmacology of Marihuana, ed. by M.C. Braude and S. Szara, pp. 667-670, Raven Press, New York, 1976.

35. Cohen, S.: The 94-day cannabis study. Ann. NY Acad. Sci. 282: 211-220, 1976.

36. Cohen, S., and Stillman, R.C.: The Therapeutic Potential of Marihuana, 515 pp., Plenum Press, New York, 1976.

37. Colls, B.M., Ferry, D.G., Gray, A.J., Harvey, A.J., and McQueen, E.G.: The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy. N.Z. Med. J. 91: 449-151, 1980.

38. Comitas, L.: Cannabis and work in Jamaica: a refutation of the amotivational syndrome. Ann. NY Acad. Sci. 282: 24-32, 1976.

39. Consroe, P.F., Wood, G.C., and Buchsbaum, H.: Anticonvulsant nature of marijuana smoking. J. Am. Med. Assoc. 234: 306-307, 1975.

40. Cooler, P., and Gregg, J.M.: Effect of delta-9-tetrahydrocannabinol on intraocular pressure in humans. South. Med. J. 70: 951-954, 1977.

41. Copeland, K.C., Underwood, L.C., and Van Wyk, J.J.: Marijuana smoking and pubertal arrest. J. Pediatr. 96: 1079-1980, 1980.

42. Cousens, K., and Dimascio, A.: Delta-9-THC as an hypnotic. An experimental study of three dose levels. Psychopharmacologia 33: 355-364, 1973.

43. Crancer, A., Dille, J.M., Delay, J.C., Wallace, J.E., and Haykins, M.D.: Comparison of the effects of marijuana and alcohol on simulated driving performance. Science (Wash. DC) 164: 851-854, 1969.

44. Cronin, C.M., Sallan, S.E., Gelber, R., Lucas, V.S., and Laszlo, J.: Antiemetic effect of intramuscular levantradol in patients receiving antiemetic chemotherapy. J. Clin. Pharmacol. 21: 43S-50S, 1981.

45. Cushman, P., and Khurana, R.: A controlled cycle of tetrahydrocannabinol smoking: T and B cell rosette formation. Life Sci. 20: 971-980. 1977.

46. Dornbush, R., Clare, G., Zaks, A., Crown, P., Volavka, I., and Fink, M.: Twenty-one day administration of marihuana in male volunteers. In Current Research in Marihuana, ed by M. Lewis, pp. 115-127, Academic Press, new York, 1972.

47. Fehr, K.A., and LeBlanc, A.E.: Residual learning deficit after heavy exposure to cannabis or alcohol in rats. Science (Wash. DC) 192: 1249-1251, 1976.

48. Feinberg, I., Jones, R., Walker, J., Caveness, C., and Floyd, E.: Effects of marijuana extract and tetrahydrocannabinol on electroencephalographic sleep patterns. Clin. Pharmacol. Ther. 19: 782-794, 1976.

49. Fink, M., Volavka, J., Panayiotopoulos, C. and Stefanis, C.: Quantitative EEG studies of marihuana, delta-9-THC, and hashish in man. In Pharmacology of Marijuana, ed. by M. Braude and S. Szara, pp. 383-392, Raven Press, New York, 1976.

50. Fleischman, R.W., Hayden, D.W., Rosenkrantz, H., and Braude, M.C.: Teratologic evaluation of delta-9-tetrahydrocannabinol in mice, including a review of the literature. Teratology 12: 47-50, 1975.

51. Frank, I., Lessin, P., Tyrrell, Hahn, P., and Szara, S.: Acute and cumulative effects of marijuana smoking on hospitalized subjects: a 36-day study. In Pharmacology of Marijuana, ed. by M. Braude and S. Szara, pp. 673-680, Raven Press, New York, 1976.

52. Freemon, F.R.: The effect of delta-9-tetrahydrocannabinol on sleep. Psychopharmacologia 35: 39-44, 1974.

53. Fried, P.A., Buckingham, M., and Von Kulmiz, P.: Marijuana use during pregnancy and perinatal risk factors. Am. J. Obstet. Gynecol. 146: 992-994, 1983.

54. Fried, P.A>, and Charlebois, A.T.: Cannabis administered during pregnancy: first and second generation effects in rats. Physiol. Psychol. 7: 307-310, 1979.

55. Frytak, S., Moertel, C., O'Fallon, J., Creagan, E., O'Connell, M., Schutt, A., and Schwartau, N.: Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. Ann. Int. Med. 91: 825-830, 1979.

56. Gilbert, P.E.: A comparison of THC, nantradol, nabilone, and morphine in the chronic spinal dog. J. Clin. Pharmacol. 21: 311S-319S, 1981.

57. Goldstein, H., Harclerode, J., and Nyquist, S.E.: Effects of chronic administration of delta-9-tetrahydrocannabinol and cannabidiol on rat testicular esterase isozymes. Life Sci. 20: 951-954, 1977.

58. Gong, H., Jr., Tashkin, D.P., Simmons, M.S., Calvarese, B., and Shapiro, B.J.: Acute and subacute branchial effects of oral cannabinoids. Clin. Pharmacol. Ther. 35: 26-32, 1984.

59. Gralla, R.J., Itri, L.M., Pisko, S.E., Sqillante, A.E., Kelsen, D.P., Braun, D.W., Jr., Borden, L.A., Brown, T.J., and Young, C.W.:Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 303: 905-909, 1981.

60. Green, K.: Marihuana and the eye. Invest. Opthalmol. 14: 261-263, 1975.

61. Green, K., and Roth, M.: Marijuana in the medical management of glaucoma. Perspect. Opthalmol. 4: 101-105, 1980.

62. Green, K., Wynn, H., and Bowman, K.A.: A comparison of topical cannabinoids on intraocular pressure. Exp. Eye Res. 27: 239-246, 1978.

63. Greenland, S., Staisch, K.J., Brown, N., and Gross, S.J.: The effects of marijuana use during pregnancy. I. A preliminary epidemiologic study. Am. J. Obstet. Gynecol. 143: 408-413, 1982.

64. Grinspoon, L: Marijuana Reconsidered, pp 218-230, Harvard University Press, Cambridge, MA, 1971.

65. Gross, H., Ebert, M.H., Faden, V.B., Goldberg, S.C., Kaye, W.H., Caine, E.D., Hawks, R., and Zinberg, N.: A double-blind trial of delta-9-tetrahydrocannabinol in primary anorexia nervosa. J. Clin. Psychopharmacol. 3: 165-171, 1983.

66. Gupta, S., Grieco, M.A., and Cushman, P.: Impairment of rosette forming T lymphocytes in chronic marihuana smokers. N. Engl. J. Med. 291: 874-877, 1974.

67. Halikas, J.A.: Marijuana use and psychiatric illness. In Marijuana: Effects on Human Behavior, ed. by L.L. Miller, pp. 265-302, Academic Press, New York, 1974.

68. Halikas, J.A., Goodwin, D.W., and Guze, S.B.: Marihuana use and psychiatric illness. Arch. Gen. Psychiatry 27: 162-165, 1972.

69. Halikas, J.A., Welles, R.A., Morse, C.L., and Hoffman, R.G.: Regular marijuana use and its effect in psychosocial variables: a longitudinal study. Comp. Psychiatry 24: 229-235, 1983.

70. Ham, M., and De Jong, Y.: Effects of delta-9-tetrahydrocannabinol and cannabidiol on blood glucose concentrations in rabbits and rat. Pharm. Weekbl. 110: 1157-1161, 1975.

71. Harding, T., and Knight, F.: Marihuana modified mania. Arch. Gen. Psychiatry 29: 635-637, 1973.

72. Harman, J., and Aliapoulios, M.A.: Marijuana induced gynecomastia: clinical and laboratory experience. Surg. Forum 25: 423-425, 1974.

73. Heath, R.C., Fitzjarrell, A.T., Fontana, C.J., and Casey, R.E.: Cannabis sativa: effects on brain function and ultrastructure in rhesus monkeys. Biol. Psychiatry 15: 657-690, 1980.

74. Henderson, R.L., Tennant, F.S., and Guerney, R.: Respiratory manifestations of hashish smoking. Arch. Otolaryncol. 95: 248-251, 1972.

75. Hepler, R.S., and Frank, I.M.: Marijuana smoking and intraocular pressure. J. Am Med. Assoc. 217: 1392-1394, 1971.

76. Herha, J., and Obe, G.: Chromosomal damage in chronic users of cannabis. Pharmakopsychiatrie 7: 328-337, 1974.

77. Herman, T.S., Einhorn, L.H., Jones, S.E., Nagy, C., Chester, A.B., Dean, J.C., Furnas, B., Williams, S.D., Leigh, S.A., Dorr, R.T., and Moon, T.E.: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N. Engl. J. Med. 300: 1295-1298, 1979.

78. Hill, S.Y., Schwin, R., Goodwin, D.W., and Powell, B.J.: Marihuana and pain. J. Pharmacol. Exp. Ther. 188: 415-418, 1974.

79. Hine, B., Torrelio, M., and Gershon, S.: Interactions between cannabinidiol and delta-9-THC during abstinence in morphine dependent rats.

Life Sci. 17: 851-858, 1975.

80. Hollister, L.E.: hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin. Pharmacol. Ther. 12: 44-49, 1971.

81. Hollister, L.E., Gillespie, H.K., Ohlsson, A., Lindgren, J.E., Wahlen, A., and Agurell, S.: Do plasma concentrates of delta-9-tetrahydrocannabinol reflect the degree of intoxication? J. Clin. Pharmacol. 21: 1715-1775, 1981.

82. Hollister, L.E., Overall, J.E., and Gerber, M.L.: Marihuana and setting. Arch. Gen. Psychiatry 32: 798-801, 1975.

83. Hollister, L.E., and Reaven, G.M.: Delta-9-tetrahydrocannabinol and glucose tolerance. Clin. Pharmacol. Ther. 16: 297-302, 1974.

84. Hollister, L.E., Richards, R., and Gillespie, H.: Comparison of tetrahydrocannabinol and synhexyl in man. Clin. Pharmacol. Ther. 9: 783-791, 1968.

85. Hollister, L.E., and Tinklenberg, J.R.: Subchronic oral doses of marihuana extract. Psychopharmacologia 29: 247-252, 1973.

86. Huber, G.L., Pochay, V.E., Percira, W., Shen, J.W., Hinds, W.C., First, M.W., and Sornberger, G.C.: Marijuana, tetrahydrocannabinol, and pulmonary antibacterial defenses. Chest 77: 403-410, 1980.

87. Idanpaan-Heikkila, J., Fritchie, E.G., Englert, L.F., Ho, T.B., and McIsaac, W.M.: Placental transfer of tritiated delta-1-tetrahydrocannabinol. N. Engl. J. Med. 281: 330, 1969.

88. Isbell, H., Gorodetsky, C.W., Jasinski, D., Clausen, V., Von Spulak, F., and Korte, F.: Effects of (-) delta-9-tetrahydrocannabinol in man. Psychopharmacologia 11: 184-188, 1967.

89. Jain, A.K., Ryan, J.R., McMahon, F.G., and Smith, G.: Evaluation of intramuscular levontradol and placebo in acute postoperative pain. J. Clin. Pharmacol. 21: 320S-326S, 1981.

90. Janowsky, D.S>, Meacham, M.P., Blaine, J.D., Schoor, M., and Bozzetti, L.P.: Marihuana effects on simulated flying ability. Am. J. Psychiatry 133: 384-388, 1976.

91. Johnson, S., and Domino, E.F.: Some cardiovascular effects of marihuana smoking in normal volunteers. Clin. Pharamacol. Ther. 12: 762-768, 1971.

92. Jones, R.C.: Cannabis and health. Annu. Rev. Med. 34: 247-253, 1983.

93. Jones, R.T., and Benowitz, N.: The 30-day trip-clinical studies of cannabis tolerance and dependence. In Pharmacology of Marihuana, ed. by M.C. Braude and S. Szara, pp 627-642, Raven Press, New York, 1976.

94. Kanter, S.L., and Hollister, L.E.: Marihuana metabolites in urine of man. VII. Excretion patterns of acidic metabolites detected by sequential thin-layer chromatography. Res. Commun. Chem. Pathol. Pharmacol. 17: 421-431, 1977.

95. Kaymakcalan, S.: Tolerance to and dependence on cannabis. Bull. Narc. 25: 39-47, 1973.

96. Keeler, M.H., and Moore, E.: Paranoid reactions while using marihuana. Dis. Nerv. Syst. 35: 535-536, 1974.

97. Keplinger, M.L.: The effect of natural and synthetic delta-9-tetrahydrocannabinol on reproductive and lactation performance in albino rats. Toxicol. Appl. Pharmacol. 25: 449, 1973.

98. Kolansky, H., and Moore, W.T.: Toxic effects of chronic marihuana use. J. Am. Med. Assoc. 222: 35-40, 1972.

99. Kolodny, R.C., Leasin, P., Tora, G., Masters, W.H., and Cohen, S.: Depression of plasma testosterone with acute marihuana administration. In Pharmacology of Marihuana, ed by M.C. Braude and S. Szara, pp. 217-225, Raven Press, New York, 1976.

100. Kolodny, R.C., Masters, W.H., Kolodny, R.M., and Toro, G.: Depression of plasma testosterone levels after chronic intensive marihuana use. N. Engl. J. Med. 290: 872-874, 1974.

101. Kuehnle, J., Mendelson, J.H., Davis, K.R., and New, P.F.J.: Computed tomographic examination of heavy marihuana smokers. J. Am. Med. Assoc. 237: 1231-1232, 1977.

102. Kupfer, D.J., Detre, T. Koral, J., and Fajans, P.: A comment on "Amotivational Syndrome" in marijuana smokers. Am. J. Psychiatry 130: 1319-1321, 1973.

103. Lau, R.J., Tubergen, D.G., Barr, M., Jr., Domino, E.F., Benowitz, N. and Jones, R.T.: Phytohemagglutinin-induced lymphocyte transformation in humans receiving delta-9-tetrahydrocannabinol. Science (Wash. DC) 192: 805-807, 1976.

104. Lemberger, L.: Potential therapeutic usefulness of marihuana. Annu. Rev. Pharmacol. Toxicol. 20: 151-172, 1980.

105. Lemberger, L., Axelrod, J., and Kopin, I.J.: Metabolism and disposition of tetrahydrocannabinols in naive subjects and chronic marihuana users. Ann. NY Acad. Sci. 191: 142-154, 1971.

106. Lemberger, L., McMahon, R., Archer, R., Matsumoto, K., and Rowe, H.: Pharmacologic effects and physical disposition of delta-6a, 10a-dimethyl heptyl tetrahydrocannabinol (HMHP) in man. Clin. Pharmacol. Ther. 15: 380-386, 1974.

107. Lemberger, L., Silberstein, S.D., Axelrod, J., and Kopin, I.J.: Marihuana: studies on the disposition and metabolism of delta-9-tetrahydrocannabinol in man. Science (Wash. DC) 170: 1320-1321, 1970.

108. Leuchtenberger, C., and Leuchtenberger, R.: Correlated cytological and cytochemical studies of the effects of fresh smoke from marijuana cigarettes on growth and DNA metabolism of animal and human lung cultures. In Pharmacology of Marihuana, ed. by M.C. Braude and S. Szara, pp. 595-612, Raven Press, New York, 1976.

109. Levy, J.A., Munson, A.E., Harris, L.S., and Dewey, W.L.: Effect of delta-8-and delta-9-tetrahydrocannabinol on the immune response in mice. Pharmacologist 16: 259, 1974.

110. Lindgren, J.E., Ohlsson, A., Agurell, S., Hollister, L., and Gillespie, H.: Clinical effects and plasma levels of delta-9-tetrahydrocannabinol (delta-9-THC) in heavy and light users of cannabis. Psychopharmacology 74: 208-212, 1980.

111. Linn, S., Schoenbaum, S.c., Monson, R.R., Rosner, R., Stubblefield, P.C., and Ryan, K.J.: The association of marijuana use with outcome of pregnancy. Am J. Public Health 73: 1161-1164, 1983.

112. Loewe, S., and Goodman, L.S.: Anticonvulsant action of marihuana active substances. Fed. Proc. 6: 352, 1947.

113. Lucas, V.S.,Jr., and Laszlo, J.: Delta-9-tetrahydrocannabinol for refractor vomiting induced by cancer chemotherapy. J. Am. Med. Assoc. 243: 1241-1243, 1980.

114. Magliozzi, Jr., Kanter, S.L., Csernansky, J.G., and Hollister, L.E.: Detection of marijuana use in psychiatric patients by determination of urinary delta-9-tetrahydrocannabinol-11-oic acid. J. Nerv. Ment. Dia. 171: 246-249, 1983.

115. Manno, J.E., Kilsheimer, G.S., and Forney, R.B.: Response of isolated perfused rat heart to delta-9-THC. Appl. Pharmacol. 17: 311, 1970.

116. Matsuyama, S.s., Jarvik, L.F., Fu, T.K., and Yen, F.S.: Chromosomal studies before and after supervised marihuana smoking. In Pharmacology of Marihuana , ed. by M.C. Braude and S. Szara, pp. 723-729, Raven Press, New York, 1976.

117. Mellinger, G.D., Somers, R.H., Davidson, S.J., and Manheimer, D.I.: The amotivational syndrome and the collage student. Ann. NY Acad. Sci. 282: 37-55, 1976.

118. Mendelson, J.H., Kuehnle, J.C., Greenberg, I., and Mello, N.:Plasma testosterone levels before, during, and after chronic marihuana smoking. N. Engl. J. Med. 291: 1051-1055, 1974. 119. Mendelson, J.H., Kuehnle, J.C., Greenberg, I., and Mello, N.: Operant acquisition of marihuana in man. J. Pharmacol. Exp. Ther. 198: 42-53, 1976.

120. Meyer, M.E.: Psychiatric consequences of marihuana use: the state of the evidence. In Marijuana and Health Hazards: Methodologic Issues in Current Research, ed. by J.R. Tinklenberg, pp. 133-152, Academic Press, New York, 1975.

121. Mikuriya, T.: Marijuana in medicine: past, present, and future. Calif. Med. 110: 34-40, 1969.

122. Miles, C.G., Congreve, G.R.S., Givvins, R.J., Marshman, J., Devenga, P., and Hicks, R.C.: An experimental study of the effects of daily cannabis smoking on behavior patterns. Act Pharmacol. Toxicol. 34: 1-44, 1974.

123. Miranne, A.C.: Marihuana use and achievement orientation of collage students. J. Health Soc. Behav. 20: 194-199, 1979.

124. Moskowitz, H., Hulbert, S., and McGlothlin, W.: Marihuana: effect on simulated driving performance. Accid. Anal. Prev. 8: 45-50, 1976.

125. Munson, A.E., Harris, L.S., Friedman, M.A., Dewey, W.L., and Carchman, R.A.: Antineoplastic activity of cannabinoids. J. Natl. Cancer Inst. 55: 597-602, 1975.

126. Nahas, G.G., Suciv-Foca, N., Armand, J.P.,and Morishima, A.: Inhibition of cellular mediated immunity in marihuana smokers. Science (Wash. DC) 183: 419-420, 1974.

127. Newman, L.M., Lutz, M.P., Gould, M.H., and Domino, E.F.: Delta-9-tetrahydrocannabinol and ethyl alcohol: evidence for cross tolerance in the rat. Science (Wash. DC) 17: 1022-1023, 1972.

128. Nichols, W.W., Miller, R.C., Heneen, W., Bradt, C., Hollister, L., and Kanter, S.: Cytogenetic studies on human subjects receiving marihuana and delta-9-tetrahydrocannabinol. Mutat. Res. 26: 413-417, 1974.

129. Noyes, R., Brunk, S.T., Avery, D.H., and Canter, A.: The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin. Pharmacol. Ther. 18: 84-89, 1975.

130. Ohlsson, A., Lindgren, J.E., Wahlen, A., Agurell, S., Hollister, L.E., and Gillespie, H.K.: Plasma delta-9-tetrahydrocannabinol concentration and clinical effects after oral and intravenous administration and smoking. Clin. Pharmacol. Ther. 28: 409-416, 1980.

131. Orr, L.E., McKernan, J.F., and Bloome, B.: Antiemetic effect of tetrahydrocannabinol compared with placebo and prochlorperazine in chemotherapy-associated nausea and emesis. Arch, Int. Med. 140: 1431-1433, 1980.

132. Palsson, A., Thulin, S.O., and Tunving, K.: Cannabis psychosis in south Sweden. Acta Psychiatr. Scand. 66: 311-321, 1982.

133. Persaud, T.V.N., and Ellington, A.C.: Cannabis in early pregnancy. Lancet 2: 1306, 1967.

134. Petersen, B.H., Grahan, J., and Lemberger, L.: Marihuana, tetrahydrocannabinol, and T-cell function. Life Sci. 1976: 395-400, 1976.

135. Petro, D.J., and Ellenberger, C.E.: Treatment of human spasticity with delta-9-tetrahydrocannabinol. J. Clin. Pharmacol. 21: 413S-416S, 1981.

136. Pivik, R.T., Zarcone, V., Dement, W.C., and Hollister, L.E.:Delta-9-tetrahydrocannabinol and synhexyl; effects on human sleep patterns. Clin. Pharmacol. ther. 13: 426-435, 1972.

137. Rachelefsky, G.S., and Opedz, G.: Normal and lymphocyte function in the presence of delta-9-tetrahydrocannabinol. Clin. Pharmacol. Ther. 21: 44-46, 1977.

138. Rafaelsen, O.J., Bech, P., Christiansen, T., Christrup, H., Nyboe, J., and Rafaelson, L.: Cannabis and alcohol: effects on simulated car driving. Science (Wash. DC) 179: 920-923, 1973.

139. Raft, D., Gregg, J., Ghia, J., and harris, L.: Effect of intravenous tetrahydrocannabinoids on experimental and surgical pain. Clin. Pharmacol. Ther. 21: 26-33, 1977.

140. Reeve, V.C., Grant, J.D., Robertson, W., Gillespie, H.K., and Hollister, L.E.: Plasma concentrations of delta-9-tetrahydrocannabinol and impaired motor function. Drug Alcohol Depend. 11: 167-175, 1883.

141. Reeve, V.C., Peck, R., Boland, P., and Mallory, C.: Marijuana-alcohol related driving performance study. A summary of preliminary findings. Proceedings of the Ninth International Conference on Alcohol, Drugs, and Traffic Safety, in press, 1985.

142. Renault, P., Schuster, C., Freedman, D., Sikic, B., Nebel De Mello, D., and Halaris, A.: Repeat administration of marihuana smoke to humans. Arch. Gen. Psychiatry 31: 95-102, 1974.

143. Rosenberg, C.M., Gerrein, J.R.,and Schnell, C.: Cannabis in the treatment of alcoholism. J. Stud. Alcohol 39: 1955-1958, 1978.

144. Rosenkrantz, H.: The immune response and marihuana. In Marihuana: Chemistry, Biochemistry, and Cellular Effects, ed. by G.G. Nahas, pp. 441-456, Springer Verlag, New York, 1976.

145. Roth, W.T., Tinklenberg, J.R., Kopell, B.S., and Hollister, L.E.: Continuous electrocardiographic monitoring during marihuana intoxication. Clin. Pharmacol. Ther. 14: 533-540, 1973.

146. Rottanburg, D., Robins, A.H., Ben-Arie, O., Teggin, A., and Eik, R.: Cannabis associated behavior with hypomaniac features. Lancet 2: 1364-1366, 1982.

147. Rubin, V., and Comitas, L.: Ganja in Jamaica. In A Medical Anthropological Study of Chronic Marihuana Use. Mouton, The Hague, 1975.

148. Sallan, S.E., Cronin, C., Zelen, M., and Zinberg, N.E.: Antiemetics on patients receiving chemotherapy for cancer. N. Engl. J. Med. 302: 135-138, 1980

149. Sallan, S.E., Zinberg, N.E., and Frei, E.: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N. Engl. J. Med. 293: 795-797, 1975.

150. Schaeffer, J., Andrysion, T., and Unferleider, J.T.: Cognition and long-term use of ganja (cannabis). Science (Wash. DC) 213: 465-466, 1981.

151. Silva, M.T.A., Carlini, E.A., Claussen, U., and Korte, F.: Lack of cross-tolerance in rats among delta-9-tetrahydrocannabinol (delta-9-THC), cannabis extract, mescaline, and lysergic acid diethylamide (LSD-25). Psychopharmacologia 13: 332-340, 1968.

152. Silverstein, M.J., and Lensin, P.: 2,4-Dinitrochlorobenzene skin testing in chronic marihuana users. In Pharmacology of Marihuana, ed. by M.C. Braude and S. Szara, pp. 199-203, Raven Press, New York, 1976.

153. Stanton, M.D., Mintz, J., and Franklin, R.M.: Drug flashbacks. II. Some additional findings. Int. J. Addict. 11: 53-69, 1976.

154. Staquet, M., Bron, D., Rosencweig, M., and Kenis, Y.: Clinical studies with a THC homolog (BRL-4664) in prevention of cisplatin-induced vomiting. J. Clin. Pharmacol. 21: 60S-63S, 1981.

155. Stenchever, M.A., Kunysz, T.J., and Allen, M.A.: Chromosome breakage in users of marijuana. Am. J. Obstet. Gynecol. 118: 106-113, 1974.

156. Stockings, G.T.: A new euphoriant for depressive mental states. Br. Med. J. 1: 918-922, 1947.

157. Strum, S.B., McDermed, J.E., Optell, R.W., and Riech, L.P.: Intravenous metoclopramide. An effective antiemetic in cancer chemotherapy. J. Am. Med. Assoc. 247: 1683-1686, 1982.

158. Szmanski, H.V.: Prolonged depersonalization after marijuana use. Am. J. Psychiatry 138: 231-233, 1981.

159. Tashkin, D.P., Calvarese, B.M., Simmons, M.S., and Shapiro, B.J.: Respiratory studies of seventy-four habitual marijuana smokers. Chest 78: 699-706, 1980.

160. Tashkin, D.P., Shapiro, B.J., Lee, V.E., and Harper, C.E.: Effects of smoked marihuana in experimentally induced asthma. Am Rev. Respir. Dis. 112: 377-385, 1975.

161. Tashkin, D.P., Shapiro, B.J., Lee, Y.E., and Harper, C.E.: Subacute effects of heavy marihuana smoking on pulmonary function in healthy men. N. Engl. J. Med. 294: 125-129, 1976.

162. Taylor, S.P., Vardaris, R.M., Rawtitch, A.B., Gammon, C.B., Cranston, J.W., and Lubetkin, A.L.: The effects of alcohol and delta-9-tetrahydrocannabinol on human physical aggression. Aggressive Behav. 2: 153-161, 1976.

163. Tennant, F., Jr., and Groesbeck, J.: Psychiatric effects of hashish. Arch. Gen. Psychiatry 27: 133-136, 1972.

164. Thacore, V.R., and Shukla, S.R.P.: Cannabis psychosis and paranoid schizophrenia. Arch. Gen. Psychiatry 33: 382-386, 1974.

165. The Use of Marihuana, Psychological Inquiry, ed. by M. Mendelson, A.Rossi, and R. Meyer, Plenum Press, New York, 1974.

166. Thompson, L.J., and Proctor, R.C.: Pyrahexyl in treatment of alcoholic and drug withdrawal conditions.North Carolina Med. J. 14: 520-523, 1953.

167. Tiedman, J.S., Shields, M.B., Wever, P.A., Crow, J.N., Cochetto, D.M., Harris, W.A., and Howes, J.P.: Effect of synthetic cannabinoids on elevated intraocular pressure. Opthalmology 88: 270-277, 1981.

168. Tinklenberg, J.R.: Marihuana and human aggression. In Marijuana: Effects on Human Behavior, ed. by L.L. Miller, pp. 339-357, Academic Press, New York, 1974.

169. Treffert, D.A.: Marijuana use in schizophrenia: a clear hazard. Am. J. Psychiatry 135: 1213-1215, 1978.

170. Turkanis, S.A., Cely, W., Olsen, D.M., and Kaarler, R.: Anticonvulsant properties of cannadidiol. Res. Commun. Chem. Pathol. Pharacol. 8: 231-246, 1974.

171. Vachon, L.: The smoke in marihuana smoking. N. Engl. J. Med. 294: 160-161, 1976.

172. Vachon, L., Fitzgerald, M.X., Solliday, N.H., Gould, I.A., and Gaensler, E.A.: Single-dose effect of marihuana smoke. Bronchial dynamics and respiratory-center sensitivity in normal subjects. N. Engl. J. Med. 288: 985-989, 1973.

173. Van Klingeren, B., and Ten Ham, M.: Antibacterial activity of delta-9-tetrahydrocannabinol and cannabidiol. Antonie Leeuwenhoek J. Microbiol. 42: 9-12, 1976.

174. Wada, J.A., Osawa, T., and Corcoran, M.E.: Effect of tetrahydrocannabinoids on kindled amygdaloid seizures in Senegalese baboons. Epilepsia 16: 439-448, 1975.

175. Wada, J.A., Sato, M., and Corcoran, M.E.: Antiepileptic properties of delta-9-tetrahydrocannabinol. Exp. Neurol. 39: 157-165, 1973.

176. Weil, A.T., Zinberg, N.E., and Nelson, J.M.: Clinical and psychological effects of marihuana in man. Science (Wash. DC) 162: 1234-1242, 1968.

177. West, M.E., and Lockhart, A.B.: The treatment of glaucoma using a non-psychoactive preparation of Cannabis sativa. West Indian Med. J. 29: 390, 1980.

178. White, S.C., Brin, S.C., and Janicki, B.W.: Mitogen-induced blastogenic responses to lymphocytes from marihuana smokers. Science (Wash. DC) 188: 71-72, 1975.

179. Wig, N.N., and Varma, V.K.: Patterns of long-term heavy cannabis use in North India and its effects on cognitive functions: a preliminary report. Drug Alcohol Depend. 2: 211-219, 1977.

180. Williams, E., Himmelsbach, C., Ruble, D.C., and Lloyd, B.J.: Studies in marihuana and pyrahexyl compound. Public Health Rep. 61: 1059-1083, 1946.

181.Williams, S.J., Hartley, J.P.R., and Graham, J.D.P.: Bronchodilator effect of delta-9-tetrahydrocannabinol administered by aerosol to asthmatic patients. Thorax 31: 720-723, 1976.

182. Yesavage, J.A., Leirer, V.O., Ditman, J. and Hollister. L.E.: "Hangover" effects of marijuana intoxication on aircraft pilot performance. Am. J. Psychiatry, in press, 1985.

183. Zimmerman, A.M., and McClean, D.K.: Action of narcotic and hallucinogenic agents on the cell cycle. In Drugs and Cell Cycle, ed. by A.M. Zimmerman, Padilla, and Cameron, p.67, Academic Press, New York, 1973.

184. Zimmerman, E.G., Yeager, E.P., Soares, J.R., Hollister, L.E., and Reeve, V.C.: Measurement of delta-9-tetrahydrocannabinol (THC) in whole blood samples from impaired motorists. J. Forensic Sci. 28: 957-962, 1981.

185. Zimmerman, S., Zimmerman, A.M., Cameron, I.L., and Laurence, H.L.: Delta-9-tetrahydrocannabinol, cannabidiol, and cannabinol effects on the immune response of mice. Pharmacology 15: 10-23, 1977.

TOC


"ARM YOURSELF"